A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market

USD 3,950

* Required Fields

USD 3,950

PAY BY INVOICE

Be the first to review this product

This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these drugs. Opioid drugs in the current market have a space for tamper-resistant formulations. The opioids market is segmented into relapsing neuropathic pain, acute and post-operative pain, cancer-induced pain, and moderate to severe chronic pain.

Table of Contents

Methodology and ScopeMethodology and ScopeExecutive SummaryExecutive SummaryExecutive Summary (continued)Executive Summary (continued)Executive Summary (continued)Executive Summary (continued)Executive Summary (continued)Executive Summary (continued)IntroductionIntroductionPhysician Guidelines to Opioid Therapy—Moderate to Severe Chronic PainPhysician Guidelines to Opioid Therapy—Neuropathic PainPhysician Guidelines to Opioid Therapy—Cancer-induced PainPhysician Guidelines to Opioid Therapy—Acute and Post-operative PainUS Opioid Therapeutics Market OverviewIntroduction—Chronic Pain Prevalence by SeverityOpioid Pain Market by RegionTop-selling Products in the US Opioid Therapeutics MarketOpioid Therapeutics—Percent Sales by Type of PainOpioid Therapeutics—Pain Formulation Prescription SalesOpioid Therapeutics—TRF and Non-TRF Prescription Sales Opioid Therapeutics—Estimated Peak Sales by Route of AdministrationOpioid Therapeutics Market—Pain Patch ProductsGame-changing StrategiesCompanies to WatchCompetitive LandscapeOpioid Therapeutics Market—Competitive LandscapeMarketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics MarketMarketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)Pipeline Analysis—Moderate to Severe Chronic Pain Opioid TherapeuticsPipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)Marketed Product—Neuropathic Pain Opioid TherapeuticsPipeline Analysis—Neuropathic Pain Opioid TherapeuticsPipeline Analysis—Neuropathic Pain Opioid Therapeutics (continued)Marketed Product Synopsis—Cancer-induced Pain Opioid TherapeuticsMarketed Product Synopsis—Cancer-induced Pain Opioid Therapeutics (continued)Pipeline Analysis—Cancer-induced Pain Opioid TherapeuticsMarketed Product Synopsis—Post-operative and Acute Pain Opioid TherapeuticsPipeline Analysis—Post-operative and Acute Pain Opioid TherapeuticsModerate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)Cancer-induced Pain Clinical Development Synopsis—Phase 3Post-operative and Acute Pain Clinical Trial Design Comparison—Phase 3Timeline TransparencyEstimated US Product Launch TimelinePre-launch Products Clinical Program—Remoxy and HYD TabletsPipeline Products Clinical Phase 3 Studies—BEMA Buprenorphine, COL-003, NucyntaPipeline Products Clinical Phase 3 Studies—ZalvisoLate-stage Development—Product DashboardsProduct Dashboard: Remoxy (Durect/Pain Therapeutics)Product Dashboard: BEMA Buprenorphine (Endo Pharmaceuticals/Biodelivery)Product Dashboard: HYD Tablet (Purdue Pharma)Product Dashboard: COL-003/Oxycodone DETERx (Collegium)Product Dashboard: Nucynta Extended Release (Grünenthal/J&J)Product Dashboard: MoxDuo Immediate Release (Actavis/QRxPharma)The Last WordThe Last WordLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 31-Oct-17

Region : North America

Release Date : 17-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.